中国迟发性运动障碍的药物治疗和研究现状及国内外差距

The current status of drug therapy and research on tardy movement disorder in China and the differences at home and abroad

迟发性运动障碍(tardive dyskinesia,TD)是一种因长期使用抗精神病药而引发的严重药物不良反应,缺乏有效的治疗方法。国内目前已尝试多种药物治疗TD,部分药物具有一定的疗效。然而,相对国外已经批准新药且疗效确切的治疗现状,我国TD治疗与之有较大差距。新型单胺类囊泡转运体2(vesicular monoamine transporter 2,VMAT2)抑制剂的应用和相关研究是中国TD治疗的趋势和方向之一。

Tardive dyskinesia(TD)is a serious adverse drug reaction caused by long-term use of antipsychotics,and there has been a lack of effective treatment.TD has been treated with several drugs in China,and some drugs have certain efficacy.However,TD therapy in China is different from foreign countries which have approved new drugs and have definite therapeutic effects.The application and research of novel VMAT2 inhibitors is one of the trends and directions of TD therapy in China.